The main goal of the study was to validate, in an independent patients' cohort, the predictive significance of TXR1–TSP1 expression in different histologies of NSCLC and across with chemotherapy regimens combining docetaxel with platinum compounds (DC) or gemcitabine (DG). The gene discussed is PRR13; the disease is non-small cell lung carcinoma.